The cancer biomarkers market was valued at US$ 18,436.36 million in 2022 and is likely to reach US$ 34,857.12 million by 2031 it is estimated to grow at a CAGR of 11.1% during 2022-2031
Biomarker, a biological molecule, is found in blood, tissues, or other body fluids that is a sign of a standard or abnormal process. A biomarker is used to see how well the body responds to a treatment for a disease or condition.
Market Insights
New Product Launches and FDA Approvals along with Technological Advancement Drive Market Growth
Market players are manufacturing a wide range of cancer biomarkers that offer maximum advantages and early diagnosis. In April 2021, Amgen launched the Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
Moreover, in March 2022, Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.
Furthermore, in December 2019, BioGenex launched three new primary immunohistochemistry (IHC) antibodies including CD8A, CD163, and CD56 for cancer diagnosis.
Additionally, recent advances in cancer immunotherapies have emerged in long-lasting clinical responses in patients. Cancer immunotherapies are rapidly replacing traditional treatment standards and expanding the therapeutic landscape for cancer patients. Researchers are focused on finding molecules in the blood that can signal the appearance of cancers. For the diagnosis of ovarian and prostate cancers, the cancer antigen (CA)125 and prostate-specific antigen (PSA) are used alongside other tests.
Additionally, advancements in high-throughput omics technologies, including genomics, proteomics, transcriptomics, and metabolomics, accelerated the pace of biomarker discovery. Recently, the concept of identifying circulating tumor DNA through a liquid biopsy has moved to clinical reality. The Society for Immunotherapy of Cancer (SITC) reconvened biomarker for an Immune Task Force to review the state-of-the-art technologies, identify current hurdlers, and make recommendations for the field. Therefore, recent technological advancement has enabled many potential biomarkers and renewed in developing new biomarkers and drive the growth of cancer biomarkers market.
Strategic Insights
Market Insights - Opportunities
Emerging Markets in Developing Countries to Provide Lucrative Opportunities for Market during Forecast Period
Emerging markets such as Asia Pacific are creating ample opportunities for significant market players to expand their business. Most of the major players focus on emerging countries such as India, China, and others owing to a large number of cancer patients and the growth of medical tourism in developing countries. Most of the emerging countries are preferred place for medical tourism.
As per the Australian Institute of Health and Welfare, 151,000 new cases of cancer are diagnosed in 2021. Furthermore, according to the Malaysia Healthcare Travel Council, in 2021, more than 2 million visited Malaysia for healthcare purposes doubling the medical tourism revenue to ~680 million. The low cost of surgeries and advanced technologies with less waiting time for procedures in the region are likely to boost the demand for cancer biomarkers.
Therefore, growing medical tourism in emerging countries and increasing cancer prevalence in Asia Pacific are anticipated to provide significant growth opportunities to the players operating in the cancer biomarkers market during the forecast period.
Biomarker Type-Based Insights
The cancer biomarkers market, based on biomarker type, is segmented into genetic biomarkers, protein biomarkers, and others. The protein biomarker segment held the largest share of the market in 2022 and is anticipated to register the highest growth rate during the forecast period.
Profiling Technology-Based Insights
The cancer biomarkers market, by profiling technology, is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. The omics technologies segment held the largest market share in 2022 and is anticipated to register the highest growth rate during 2022–2031.
Cancer Type-Based Insights
The cancer biomarkers market, based on cancer type, is segmented into breast cancer, lung cancer, prostate cancer, leukemia, bladder cancer, and others. In 2022, the other segment held the largest share of the market. However, the lung cancer segment is expected to register the fastest growth rate in the coming years.
Application-Based Insights
Based on application, the cancer biomarkers market is segmented into diagnostics, research and development, prognostics, and others. In 2022, the prognostics segment held the largest share of the market. Also, the same segment is anticipated to register the highest CAGR during the forecast period.
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the cancer biomarkers market. A few recent key market developments are listed below:
- In March 2022, Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.
- In March 2022, the National Cancer Institute, part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor molecular characterization, also called biomarker testing, to children, adolescents, and young adults with newly diagnosed central nervous system tumors who are being treated at hospitals that are affiliated with the Children’s Oncology Group
- In December 2019, BioGenex launched three new primary immunohistochemistry (IHC) antibodies including CD8A, CD163, and CD56 for cancer diagnosis.
- In May 2021, GE Healthcare acquires oncology biomarker maker Zionexa to further develop molecular imaging agents for cancer treatment. The company will develop and commercialise the Zionexa biomarkers and positron emission tomography (PET) imaging agent, Cerianna (fluoroestradiol F-18). Cerianna is approved by the US Food and Drug Administration for use as an adjunct to biopsy for identifying estrogen receptor (ER) positive lesions. It can aid in choosing the best therapies for recurrent or metastatic breast cancer patients.
- In April 2021, Amgen launched the Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
Company Profiles
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd
- Illumina Inc
- Bio-Rad Laboratories Inc
- QIAGEN
- bioMérieux Inc
- Creative Diagnostics Hologic Inc
- Myriad Genetic Inc
- Quest Diagnostics
Cancer Biomarkers Market Report Analysis
-
CAGR (2023 - 2031)11.10% -
Market Size 2023
US$ 20.48 Billion -
Market Size 2031
US$ 47.54 Billion
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Hologic Inc.
- Quest Diagnostics Incorporated
- bioMérieux SA
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Biomarker Type
- Protein Biomarkers
- Genetic Biomarkers
By Profiling Technology
- Omics Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics
- Bioinformatics
By Cancer Type
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Leukemia
- Bladder Cancer
By Application
- Prognostics
- Diagnostics
- ResearchDevelopment
Cancer Biomarkers Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 20.48 Billion |
| Market Size by 2031 | US$ 47.54 Billion |
| Global CAGR (2023 - 2031) | 11.10% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Biomarker Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Biomarker Type, Profiling Technology, Cancer Type, and Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Unfavorable regulatory and reimbursement scenario is the major factor hindering the market growth.
Based on biomarker types, the protein biomarker segment held largest share of the market and protein biomarker segment is projected to register the highest CAGR during the forecast period.
The cancer biomarkers report contains forecast of 2019 to 2027.
The key factors that are driving growth of the market are growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements.
National Cancer Institute defined biomarker as a biological molecule found in blood, or tissues or other body fluids that is a sign of a standard or abnormal process. A biomarker is employed to ascertain however well the body responds to a treatment for a malady or condition. Cancer biomarkers area unit the molecules that aid within the examination similarly because the treatment of various kinds of cancer. These molecules are often evaluated by aggregation samples like stool, neoplasm tissue, blood, urine, or alternative tissues or bodily fluids.
Trends and growth analysis reports related to Biotechnology : READ MORE..
The List of Companies
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Hologic Inc.
- Quest Diagnostics Incorporated
- bioMérieux SA
- Creative Diagnostics
Get Free Sample For